Long-Acting HIV Treatment: 5 Myths and Realities

Long-Acting HIV Treatment: 5 Myths and Realities

1 of 7
Next >

Long-acting antiretrovirals: Are they the future of HIV treatment or will the future pass them by?

Long-acting antiretrovirals: Are they the future of HIV treatment or will the future pass them by?

As research progresses on long-acting antiretroviral therapy (LA-ART) for HIV -- also sometimes referred to as extended-release (ER) antiretroviral therapy -- experts disagree about the impact it will have on clinical care. There is both optimism and pessimism regarding LA-ART, and sometimes they come from the same person, as was the case at CROI 2017 in Seattle, Washington.

At this major gathering of HIV researchers and clinical experts, Charles W. Flexner, M.D., a professor of medicine at Johns Hopkins University, gave a presentation in which he refuted what he regarded as five common LA-ART myths -- while retaining his own healthy dose of skepticism about LA-ART's ultimate value for people living with HIV.

Image credit: Myles Helfand.